-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The TOURMALINE-MM phase 3 study (NCT02181413) showed that after autologous stem cell transplantation (ASCT) in patients with multiple myeloma , maintenance therapy with ixazomib had an improved progression-free survival rate compared with placebo.
Stem cell management
The researchers randomly assigned patients at a ratio of 3:2 to receive ixazomib (n = 395) or placebo (n = 261), respectively, and received treatment on days 1, 8 and 15 of the 28-day cycle for a period of approximately 2 years or until disease/toxicity progresses.
The results showed that the incidence of grade ≥3 AEs in the ixazomib group (19%) was higher than that in the placebo group (5%), but the rate of discontinuation due to AEs was similar (7% vs.
In summary, the results of this study indicate that ixazomib is an effective and tolerable option for maintenance therapy after ASCT.
Original source:
Martin Kaiser, et al.
Leave a message here